Financing ·
Aclaris Therapeutics entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor…
ACRSAclaris Therapeutics, Inc.
Aclaris Therapeutics entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald to offer and sell shares of common stock through at-the-market offerings. This agreement amends the previous facility dated February 27, 2025, which had a $100.0 million limit. The new arrangement allows sales at the Company's sole discretion based on market conditions and instructions regarding price or size limits. The Company will pay a commission of 3.0% of gross sales proceeds to the agents. Aclaris Therapeutics operates in the biopharmaceutical industry, developing treatments for inflammatory diseases.